PRME:NSD-Prime Medicine, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.83

Change

0.00 (0.00)%

Market Cap

N/A

Volume

1.28M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

N/A

USD 126.22B
VRTX Vertex Pharmaceuticals Inc

N/A

USD 120.00B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 35.16B
ARGX argenx NV ADR

N/A

USD 32.02B
MRNA Moderna Inc

N/A

USD 25.25B
BGNE BeiGene Ltd

N/A

USD 22.45B
SMMT Summit Therapeutics PLC

N/A

USD 17.92B
RPRX Royalty Pharma Plc

N/A

USD 16.34B
UTHR United Therapeutics Corporatio..

N/A

USD 15.71B
PCVX Vaxcyte Inc

N/A

USD 14.50B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -56.77% 22% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.77% 22% F 13% F
Trailing 12 Months  
Capital Gain -65.43% 20% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.43% 20% F 12% F
Trailing 5 Years  
Capital Gain -81.07% 39% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.07% 38% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain -19.73% 30% F 17% F
Dividend Return -19.73% 30% F 17% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 24.94% 93% A 69% C-
Risk Adjusted Return -79.11% 16% F 10% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.